Company / FCF Margin
Stoke Therapeutics, Inc. FCF Margin History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
24.3%
FY2025
5-year range
-941.7% / 24.3%
FY2022-FY2025
Trend
+102.6%
vs FY2024
Sector context
#21 of 134
Health Care
What the data says
Stoke Therapeutics, Inc.'s fcf margin of 24.3% is higher than 84% of companies in the Health Care sector (FY2025). Improved from -288.8% to 24.3% over the past 2 years.
Based on SEC 10-K filings.
24.3% in FY2025 with a 3-year CAGR of +573.4%. Top quartile in the Health Care sector.
Improved from -288.8% to 24.3% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +573.4pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Top 16% in Health CareTop 16% of 134This company 24.3% Sector average -637.8%
▼
+103.8% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 102.6% year-over-year.
- Currently 662.1pp above the Health Care sector average.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 24.3% | +102.6% |
| FY2024 | -941.7% | -226.1% |
| FY2023 | -288.8% | +47.4% |
| FY2022 | -549.0% | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026